SCHEMBL15660607

SCHEMBL15660607

OCCc1ccc(Nc2nc(-c3cccc(Cl)c3)nc3c2SCCC3)cc1

nearest known ligand 0.61

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 20/20 0.61
▸ PDE4D Q08499 14/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15659184 0.94 PDE4B (0.54) PDE4BPDE4D
SCHEMBL15658466 0.87 PDE4B (0.81) PDE4BPDE4D
SCHEMBL23586235 0.86 PDE4B (0.59) PDE4BPDE4D
SCHEMBL15657624 0.86 PDE4B (0.68) PDE4BPDE4D
SCHEMBL15658630 0.86 PDE4B (0.58) PDE4BPDE4D
SCHEMBL15947945 0.85 PDE4B (0.67) PDE4BPDE4D
SCHEMBL23586199 0.85 PDE4B (0.61) PDE4BPDE4D
SCHEMBL15658133 0.84 PDE4B (0.69) PDE4BPDE4D
SCHEMBL23586242 0.83 PDE4B (0.65) PDE4BPDE4D
SCHEMBL23586247 0.83 PDE4B (0.59) PDE4BPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264169-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners (US) 2025-04-01 — — US disclosed
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-11-02 — — US disclosed
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-11-02 — — US disclosed
US-11767334-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2023-09-26 — — US disclosed
US-11767334-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2023-09-26 — — US disclosed
US-20230024240-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-01-26 — — US disclosed
US-20230024240-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-01-26 — — US disclosed
EP-3842420-B1 HETEROARYL INHIBITORS OF PDE4 TETRA DISCOVERY PARTNERS LLC (US) 2022-12-07 — — EP disclosed
EP-3842420-B1 HETEROARYL INHIBITORS OF PDE4 TETRA DISCOVERY PARTNERS LLC (US) 2022-12-07 — — EP disclosed
US-11401286-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2022-08-02 — — US disclosed
US-20160137672-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2016-05-19 — — US disclosed
US-20160137672-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2016-05-19 — — US disclosed
US-9221843-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2015-12-29 — — US disclosed
US-9221843-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2015-12-29 — — US disclosed
EP-2912019-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners LLC (US) 2015-09-02 — — EP disclosed
US-20150119362-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2015-04-30 — — US disclosed
US-20150119362-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2015-04-30 — — US disclosed
WO-2014066659-A9 HETEROARYL INHIBITORS OF PDE4 TETRA DISCOVERY PARTNERS, LLC. (US) 2015-02-12 — — WO disclosed
WO-2014066659-A9 HETEROARYL INHIBITORS OF PDE4 TETRA DISCOVERY PARTNERS, LLC. (US) 2015-02-12 — — WO disclosed
WO-2014066659-A1 HETEROARYL INHIBITORS OF PDE4 TETRA DISCOVERY PARTNERS, LLC. (US) 2014-05-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024240-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C PDE4B 2/4885PDE4D 9/4885
US-20150119362-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C PDE4B 2/4885PDE4D 9/4885
US-11401286-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C PDE4B 2/4885PDE4D 9/4885
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C PDE4B 2/4885PDE4D 9/4885
US-11767334-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C PDE4B 2/4885PDE4D 9/4885
US-12264169-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C PDE4B 2/4885PDE4D 9/4885
US-20160137672-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C PDE4B 2/4885PDE4D 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback